A 28-year-old woman from Maharashtra with a 6-month history of painless nodules on the shins, fever, and cough undergoes chest imaging showing bilateral hilar lymphadenopathy. Skin biopsy of the nodule shows non-caseating granulomas. Which investigation would be most appropriate to differentiate this condition from tuberculosis?

## Differentiating Sarcoidosis from Tuberculosis ### Clinical Presentation The patient presents with the classic triad of **Löfgren syndrome** (acute sarcoidosis): - Erythema nodosum (painless nodules on shins) - Bilateral hilar lymphadenopathy - Constitutional symptoms (fever, cough) The skin biopsy already demonstrates **non-caseating granulomas**, which is the hallmark of sarcoidosis. The critical question is: which investigation best differentiates this from tuberculosis, especially in an endemic region like Maharashtra, India? ### Why TB-IGRA (Interferon-Gamma Release Assay) is the Most Appropriate Investigation **High-Yield:** In a patient where the biopsy has already shown non-caseating granulomas, the TB-IGRA (QuantiFERON-TB Gold or T-SPOT.TB) is the most appropriate *investigation* to differentiate sarcoidosis from tuberculosis because: 1. **Specificity for Mycobacterium tuberculosis:** IGRA detects T-cell responses to TB-specific antigens (ESAT-6 and CFP-10), which are absent in *M. bovis* BCG and most non-tuberculous mycobacteria. A **negative IGRA strongly supports sarcoidosis** over TB. 2. **Non-invasive and practical:** It requires only a blood sample and does not require repeating an invasive biopsy. 3. **Endorsed by guidelines:** In TB-endemic countries, IGRA is recommended as a key tool to rule out TB infection when sarcoidosis is suspected (Harrison's 21e, Ch. 335; RNTCP guidelines). 4. **Sarcoidosis patients typically test IGRA-negative** (unless co-infected), whereas active or latent TB patients test positive. | Investigation | Sensitivity for TB | Specificity for TB vs. Sarcoidosis | Practicality | |---|---|---|---| | **TB-IGRA** | ~80–90% | High (TB-specific antigens) | Blood test, non-invasive | | Sputum AFB smear | 40–60% | Low (negative in both) | Requires sputum, 3 samples | | Repeat biopsy for caseation | N/A | Moderate (already non-caseating) | Invasive, redundant | | Serum lysozyme | N/A | Low (elevated in both) | Non-specific | ### Why Other Options Are Suboptimal **Option B – Caseation necrosis on repeat biopsy:** - The biopsy has **already been performed** and shows non-caseating granulomas. Repeating the biopsy to assess caseation is redundant and invasive. - AFB staining on the *existing* biopsy specimen would be more logical, but even that is less definitive than IGRA. - Repeating biopsy is not standard clinical practice for this differential. **Option A – Sputum smear microscopy for AFB:** - Sensitivity is only 40–60% for pulmonary TB; a negative result does not rule out TB. - Completely negative in sarcoidosis, so it cannot reliably differentiate the two conditions. **Option D – Serum lysozyme:** - Elevated in sarcoidosis but also in TB and other granulomatous diseases. - Non-specific; not used for differentiation in routine clinical practice. ### Diagnostic Approach **Clinical Pearl:** In TB-endemic regions like India, TB-IGRA is the investigation of choice to exclude TB when non-caseating granulomas are found on biopsy. A negative IGRA, combined with the clinical picture of Löfgren syndrome, strongly supports a diagnosis of sarcoidosis. Serum ACE and calcium levels provide additional supportive evidence. [cite: Harrison 21e Ch. 335; Robbins & Cotran Pathologic Basis of Disease 10e Ch. 15; RNTCP/NTEP Guidelines]